Obesity and Its Impact on Drug Therapy
- 111 Downloads
The prevalence of obesity, defined as a body mass index (BMI) of 30 or more, has dramatically increased over the past 20 years. In 1990, the prevalence of obesity was less than 15% in each of 44 surveyed US states. By 2010, every state in the US had an obesity prevalence of more than 20%. Although this trend appears to be plateauing across all ages, approximately 34% of US adults and 17% of children and adolescents are now obese.[2,3] Obesity has numerous effects on health, which are yet to be fully understood, not the least of which is how we dose therapeutic drugs in these patients. Simple adjustments based on total body weight or some component of it (e.g. lean body weight) cannot be applied across all patients or drugs, since changes in blood volume, organ size or metabolic capacity, and other factors are not uniformly related to body weight alone.[4,5]
Ghobadi et al. have taken an important step forward to quantify the impact of obesity and morbid obesity (BMI ≥40 kg/m2) on...
KeywordsObesity PBPK Model Drug Pharmacokinetic Drug Development Process Lean Body Weight
Dr Neely holds an academic licence for Simcyp software. He has received no monetary support from Simcyp. Dr Louie has no conflicts of interest that are directly relevant to the content of this commentary.
- 1.Centers for Disease Control and Prevention. Overweight and obesity: data and statistics. US obesity trends [online]. Available from URL: http://www.cdc.gov/obesity/data/trends.html [Accessed 2011 Sep 9]